23 January 2026 : Clinical Research
Predicting the Effectiveness of 2 Chemotherapy Regimens Applied to Breast Cancer Patients by Nutritional and Inflammatory Status
Mehmet Salim Demir
ABCDEFG 1*, Gözde Ağdaş BCFG 1
DOI: 10.12659/MSM.951548
Med Sci Monit 2026; 32:e951548
Table 3 Comparison of treatment outcomes between ddAC-THP and TCHP neoadjuvant chemotherapy groups.
| Variables | ddAC-THP (n: 72) | TCHP (n: 40) | P value |
|---|---|---|---|
| Neoadjuvant duration (days) | 206.2±44.1 | 209.1±69.7 | 0.802 |
| Interval of neoadjuvant and surgery (days) | 52±11.2 | 54.4±13.1 | 0.784 |
| Retrieved lymph nodes (n) | 8.1±6.3 | 8.2±5.8 | 0.766 |
| Metastatic lymph nodes (n) | 1.3±3 | 1.5±2.4 | 0.522 |
| Pathological complete response | 40 (55.6%) | 20 (50%) | 0.713 |
| Tumor size | 0.359 | ||
| Complete response | 41 (56.9%) | 21 (52.5%) | |
| <1 cm | 12 (16.7%) | 9 (22.5%) | |
| 1–2 cm | 12 (16.7%) | 9 (22.5%) | |
| 2–5 cm | 7 (9.7%) | 1 (2.5%) | |
| Adjuvant radiotherapy | 64 (88.9%) | 36 (90%) | 0.855 |
| Recurrence/progression (Yes) | 16 (22.2%) | 6 (15%) | 0.501 |
| Recurrence | 0.131 | ||
| None | 57 (79.2%) | 35 (87.5%) | |
| Local | 1 (1.4%) | 2 (5%) | |
| Regional | 0 (0%) | 0 (0%) | |
| Locoregional | 3 (4.2%) | 1 (2.5%) | |
| Metastatic | 5 (6.9%) | 2 (5%) | |
| Locoregional + metastatic | 6 (8.3%) | 0 (0%) | |
| Vital atatus – alive | 61/11 (84.7%) | 39/1 (97.5%) | 0.021 |
| TCHP – docetaxel/carboplatin/trastuzumab/pertuzumab; ddAC-THP – dose-dense doxorubicin/cyclo-phosphamide followed by docetaxel/trastuzumab/pertuzumab; cm – centimeter. Continuous variables were compared using independent samples test and are presented as mean±standard deviation. Categorical variables were analyzed using the chi-squared (χ) test or Fisher’s exact test where appropriate and are reported as n (%). A two-sided value less than 0.05 was considered statistically significant. | |||